The Effect of Cysteine Peptide Ingestion on Skin Brightness, a Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Human Clinical Trial

被引:0
|
作者
Uchida, Yoshiaki [1 ]
Kaneda, Tomomi [1 ]
Ono, Mio [1 ]
Matsuoka, Masao [2 ]
Nakamura, Utano [3 ]
Ishida, Akiko [3 ]
Yamasaki, Yoshimitsu [4 ]
Takeo, Hiroki [5 ]
Sakurai, Takanobu [1 ]
机构
[1] Mitsubishi Corp Life Sci Ltd, Res & Dev Div, 1-1-3 Yurakucho,Chiyoda Ku, Tokyo 1000006, Japan
[2] M&I Sci CORP, 1-17-26 Nakatsu,Kita Ku, Osaka 5310073, Japan
[3] Pharm Foods Int Co Ltd, 1-49 Goryo-Ohara,Nishikyo Ku, Kyoto 6158245, Japan
[4] NISHI UMEDA Clin Asian Med Collaborat, 3-3-45 Umeda,Kita Ku, Osaka 5300001, Japan
[5] TAKEO Clin, Med Corp Diastep, 4-22-7 Taishido,Setagaya Ku, Tokyo 1540004, Japan
关键词
cysteine peptide; glutathione; cysteinylglycine; & gamma; -glutamylcysteine; skin brightness; safety; GLUTATHIONE METABOLISM; PIGMENTATION; BIOSYNTHESIS;
D O I
10.3390/cosmetics10030072
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Glutathione (GSH) is present in almost all human cells and has a beneficial effect on human skin brightness. Cysteinylglycine (Cys-Gly) and ?-glutamylcysteine (?-Glu-Cys) are GSH synthesis components. In this study, we defined glutathione (GSH), cysteinylglycine (Cys-Gly), and ?-glutamylcysteine (?-Glu-Cys) as cysteine peptide and performed a randomized, double-blind, placebo-controlled study to investigate the effects of orally administered cysteine peptide on human skin brightness using a CM-26d portable spectrophotometer in healthy males and females aged between 20 and 65 years old. Eligible participants were randomly allocated into three groups (cysteine peptide 45 mg: n = 16, 90 mg: n = 15, and placebo: n = 16). Each subject ingested six tablets every day for 12 weeks, and skin brightness was measured at 0, 4, 8, and 12 weeks. As a result, the 45 mg group exhibited arm brightening in a time-dependent manner, and a significant difference was observed compared to the placebo at week 12 (p = 0.028). Moreover, no serious adverse events and changes related to 270 mg study food were observed in the safety trial. Here, we suggest that cysteine peptide is a promising and safe compound for human skin brightness.
引用
收藏
页数:12
相关论文
共 50 条
  • [21] Gaboxadol in angelman syndrome: A double-blind, parallel-group, randomized placebo-controlled phase 3 study
    Keary, Christopher
    Bird, Lynne M.
    de Wit, Marie-Claire
    Hatti, Shivkumar
    Heimer, Gali
    Heussler, Helen
    Kolevzon, Alexander
    Mathews, Adera
    Ochoa-Lubinoff, Cesar
    Tan, Wen-Hann
    Yan, Ying
    Adams, Maxwell
    EUROPEAN JOURNAL OF PAEDIATRIC NEUROLOGY, 2023, 47 : 6 - 12
  • [22] Efficacy of resveratrol in the treatment of unipolar depression: double-blind randomized placebo-controlled parallel-group study
    Aftanas, L. I.
    Markov, A. A.
    Rikita, M. V.
    Danilenko, K. V.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2020, 40 : S189 - S189
  • [23] A randomized, double-blind, placebo-controlled clinical trial to investigate the effect of Cynatine® HNS on skin characteristics
    Beer, C.
    Wood, S.
    Veghte, R. H.
    INTERNATIONAL JOURNAL OF COSMETIC SCIENCE, 2013, 35 (06) : 608 - 612
  • [24] Effectiveness of quinine in treating muscle cramps: A double-blind, placebo-controlled, parallel-group, multicentre trial
    Diener, HC
    Dethlefsen, U
    Dethlefsen-Gruber, S
    Verbeek, P
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2002, 56 (04) : 243 - 246
  • [25] Postoperative periodontal pain prevention using two dexamethasone medication protocols: A double-blind, parallel-group, placebo-controlled randomized clinical trial
    Steffens, Joao Paulo
    Santos, Fabio Andre
    Pilatti, Gibson Luiz
    AMERICAN JOURNAL OF DENTISTRY, 2011, 24 (06): : 354 - 356
  • [26] Treatment of separation anxiety in dogs with clomipramine: results from a prospective, randomized, double-blind, placebo-controlled, parallel-group, multicenter clinical trial
    King, JN
    Simpson, BS
    Overall, KL
    Appleby, D
    Pageat, P
    Ross, C
    Chaurand, JP
    Heath, S
    Beata, C
    Weiss, AB
    Muller, G
    Paris, T
    Bataille, BG
    Parker, J
    Petit, S
    Wren, J
    APPLIED ANIMAL BEHAVIOUR SCIENCE, 2000, 67 (04) : 255 - 275
  • [27] Stimulation of the Prefrontal Cortex Reduces Intentions to Commit Aggression: A Randomized, Double-Blind, Placebo-Controlled, Stratified, Parallel-Group Trial
    Choy, Olivia
    Raine, Adrian
    Hamilton, Roy H.
    JOURNAL OF NEUROSCIENCE, 2018, 38 (29): : 6505 - 6512
  • [28] Efficacy of andrographolide in not active progressive multiple sclerosis: a prospective exploratory double-blind, parallel-group, randomized, placebo-controlled trial
    Ethel Ciampi
    Reinaldo Uribe-San-Martin
    Claudia Cárcamo
    Juan Pablo Cruz
    Ana Reyes
    Diego Reyes
    Carmen Pinto
    Macarena Vásquez
    Rafael A. Burgos
    Juan Hancke
    BMC Neurology, 20
  • [29] Effect of Repeated Consumption of Partially Hydrolyzed Guar Gum on Fecal Characteristics and Gut Microbiota: A Randomized, Double-Blind, Placebo-Controlled, and Parallel-Group Clinical Trial
    Yasukawa, Zenta
    Inoue, Ryo
    Ozeki, Makoto
    Okubo, Tsutomu
    Takagi, Tomohisa
    Honda, Akira
    Naito, Yuji
    NUTRIENTS, 2019, 11 (09)
  • [30] Efficacy and Safety of Dichlorphenamide for the Treatment of Periodic Paralysis: a Phase 3 Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Trial
    Burge, James
    Sansone, Valeria
    McDermott, Michael
    Smith, Patty
    Herr, Barbara
    Tawil, Alrabi
    Pandya, Shree
    Kissel, John
    Ciafaloni, Emma
    Shieh, Perry
    Ralph, Jeffrey
    Amato, Anthony
    Cannon, Stephen
    Trivedi, Jaya
    Barohn, Richard
    Crum, Brian
    Mitsumoto, Hiroshi
    Pestronk, Alan
    Meola, Giovanni
    Conwit, Robin
    Jasek, Mark
    Hanna, Michael
    Griggs, Robert
    NEUROLOGY, 2016, 86